nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—SRMS—knee—ankylosing spondylitis	0.0488	0.198	CbGeAlD
Bosutinib—BMP2K—synovial membrane of synovial joint—ankylosing spondylitis	0.0162	0.0656	CbGeAlD
Bosutinib—Gastric haemorrhage—Methylprednisolone—ankylosing spondylitis	0.0111	0.0768	CcSEcCtD
Bosutinib—Gastrointestinal toxicity—Methotrexate—ankylosing spondylitis	0.00561	0.0389	CcSEcCtD
Bosutinib—TLK1—tendon—ankylosing spondylitis	0.00455	0.0185	CbGeAlD
Bosutinib—PRKCQ—tendon—ankylosing spondylitis	0.00448	0.0182	CbGeAlD
Bosutinib—CLK3—tendon—ankylosing spondylitis	0.00421	0.0171	CbGeAlD
Bosutinib—PHKG1—tendon—ankylosing spondylitis	0.00411	0.0167	CbGeAlD
Bosutinib—EIF2AK1—tendon—ankylosing spondylitis	0.00407	0.0165	CbGeAlD
Bosutinib—FES—tendon—ankylosing spondylitis	0.00394	0.016	CbGeAlD
Bosutinib—VRK2—tendon—ankylosing spondylitis	0.00394	0.016	CbGeAlD
Bosutinib—TNIK—tendon—ankylosing spondylitis	0.00386	0.0157	CbGeAlD
Bosutinib—SYK—tendon—ankylosing spondylitis	0.00386	0.0157	CbGeAlD
Bosutinib—CDK2—tendon—ankylosing spondylitis	0.00383	0.0155	CbGeAlD
Bosutinib—STK26—tendon—ankylosing spondylitis	0.00379	0.0154	CbGeAlD
Bosutinib—CHEK2—tendon—ankylosing spondylitis	0.00366	0.0149	CbGeAlD
Bosutinib—DMPK—tendon—ankylosing spondylitis	0.00363	0.0148	CbGeAlD
Bosutinib—WEE1—tendon—ankylosing spondylitis	0.00363	0.0148	CbGeAlD
Bosutinib—STK25—tendon—ankylosing spondylitis	0.00347	0.0141	CbGeAlD
Bosutinib—PLK2—tendon—ankylosing spondylitis	0.00337	0.0137	CbGeAlD
Bosutinib—SIK3—tendon—ankylosing spondylitis	0.00335	0.0136	CbGeAlD
Bosutinib—CAMK1D—tendon—ankylosing spondylitis	0.00319	0.0129	CbGeAlD
Bosutinib—STK24—tendon—ankylosing spondylitis	0.00315	0.0128	CbGeAlD
Bosutinib—FER—tendon—ankylosing spondylitis	0.00305	0.0124	CbGeAlD
Bosutinib—MAP4K1—tendon—ankylosing spondylitis	0.00299	0.0121	CbGeAlD
Bosutinib—BTK—tendon—ankylosing spondylitis	0.00297	0.0121	CbGeAlD
Bosutinib—MAP4K2—tendon—ankylosing spondylitis	0.00289	0.0117	CbGeAlD
Bosutinib—ERBB4—tendon—ankylosing spondylitis	0.00285	0.0116	CbGeAlD
Bosutinib—STK3—tendon—ankylosing spondylitis	0.00285	0.0116	CbGeAlD
Bosutinib—Pancreatitis acute—Betamethasone—ankylosing spondylitis	0.00274	0.019	CcSEcCtD
Bosutinib—Pancreatitis acute—Dexamethasone—ankylosing spondylitis	0.00274	0.019	CcSEcCtD
Bosutinib—BMPR2—tendon—ankylosing spondylitis	0.00273	0.0111	CbGeAlD
Bosutinib—STK36—tendon—ankylosing spondylitis	0.00271	0.011	CbGeAlD
Bosutinib—MERTK—tendon—ankylosing spondylitis	0.00268	0.0109	CbGeAlD
Bosutinib—MAP4K4—tendon—ankylosing spondylitis	0.00263	0.0107	CbGeAlD
Bosutinib—BCR—tendon—ankylosing spondylitis	0.00261	0.0106	CbGeAlD
Bosutinib—MAP3K12—tendon—ankylosing spondylitis	0.00259	0.0105	CbGeAlD
Bosutinib—STK35—tendon—ankylosing spondylitis	0.00254	0.0103	CbGeAlD
Bosutinib—CSK—tendon—ankylosing spondylitis	0.00252	0.0102	CbGeAlD
Bosutinib—CSNK1A1—tendon—ankylosing spondylitis	0.00251	0.0102	CbGeAlD
Bosutinib—HCK—tendon—ankylosing spondylitis	0.00249	0.0101	CbGeAlD
Bosutinib—CLK1—tendon—ankylosing spondylitis	0.00249	0.0101	CbGeAlD
Bosutinib—ABL2—tendon—ankylosing spondylitis	0.00247	0.01	CbGeAlD
Bosutinib—BMP2K—tendon—ankylosing spondylitis	0.00244	0.00993	CbGeAlD
Bosutinib—CAMK2G—tendon—ankylosing spondylitis	0.00244	0.00993	CbGeAlD
Bosutinib—LRRK2—tendon—ankylosing spondylitis	0.00242	0.00984	CbGeAlD
Bosutinib—Pancreatitis acute—Prednisone—ankylosing spondylitis	0.00239	0.0165	CcSEcCtD
Bosutinib—PTK2B—tendon—ankylosing spondylitis	0.00236	0.00959	CbGeAlD
Bosutinib—CSNK1E—tendon—ankylosing spondylitis	0.00232	0.00943	CbGeAlD
Bosutinib—SIK1—tendon—ankylosing spondylitis	0.00229	0.00928	CbGeAlD
Bosutinib—IRAK4—tendon—ankylosing spondylitis	0.00229	0.00928	CbGeAlD
Bosutinib—EPHA4—tendon—ankylosing spondylitis	0.00226	0.00919	CbGeAlD
Bosutinib—Pericardial effusion—Methotrexate—ankylosing spondylitis	0.00225	0.0155	CcSEcCtD
Bosutinib—ULK3—tendon—ankylosing spondylitis	0.00224	0.00908	CbGeAlD
Bosutinib—MAP2K2—tendon—ankylosing spondylitis	0.00224	0.00908	CbGeAlD
Bosutinib—MAP3K7—tendon—ankylosing spondylitis	0.0022	0.00893	CbGeAlD
Bosutinib—PTK2—tendon—ankylosing spondylitis	0.00217	0.00883	CbGeAlD
Bosutinib—TBK1—tendon—ankylosing spondylitis	0.00217	0.00883	CbGeAlD
Bosutinib—IRAK1—tendon—ankylosing spondylitis	0.00213	0.00865	CbGeAlD
Bosutinib—Pericarditis—Methotrexate—ankylosing spondylitis	0.00213	0.0147	CcSEcCtD
Bosutinib—ABCB1—Methylprednisolone—ankylosing spondylitis	0.00211	0.167	CbGbCtD
Bosutinib—RPS6KB1—tendon—ankylosing spondylitis	0.00209	0.00849	CbGeAlD
Bosutinib—FGR—tendon—ankylosing spondylitis	0.00208	0.00844	CbGeAlD
Bosutinib—AXL—tendon—ankylosing spondylitis	0.00207	0.00841	CbGeAlD
Bosutinib—SLK—tendon—ankylosing spondylitis	0.00199	0.00809	CbGeAlD
Bosutinib—EPHB4—tendon—ankylosing spondylitis	0.00198	0.00803	CbGeAlD
Bosutinib—EPHA2—tendon—ankylosing spondylitis	0.00194	0.00788	CbGeAlD
Bosutinib—FYN—tendon—ankylosing spondylitis	0.00194	0.00787	CbGeAlD
Bosutinib—MAP3K3—tendon—ankylosing spondylitis	0.00189	0.00769	CbGeAlD
Bosutinib—MAP4K5—tendon—ankylosing spondylitis	0.00189	0.00769	CbGeAlD
Bosutinib—Febrile neutropenia—Prednisone—ankylosing spondylitis	0.00183	0.0127	CcSEcCtD
Bosutinib—Acne—Prednisolone—ankylosing spondylitis	0.0018	0.0125	CcSEcCtD
Bosutinib—YES1—tendon—ankylosing spondylitis	0.00175	0.0071	CbGeAlD
Bosutinib—STK10—tendon—ankylosing spondylitis	0.00173	0.00704	CbGeAlD
Bosutinib—TAOK3—tendon—ankylosing spondylitis	0.00173	0.00701	CbGeAlD
Bosutinib—Acne—Triamcinolone—ankylosing spondylitis	0.00166	0.0115	CcSEcCtD
Bosutinib—Acne—Methylprednisolone—ankylosing spondylitis	0.00165	0.0115	CcSEcCtD
Bosutinib—MAP2K5—tendon—ankylosing spondylitis	0.00155	0.00628	CbGeAlD
Bosutinib—Febrile neutropenia—Methotrexate—ankylosing spondylitis	0.00153	0.0106	CcSEcCtD
Bosutinib—CSF1R—tendon—ankylosing spondylitis	0.00151	0.00613	CbGeAlD
Bosutinib—Acne—Dexamethasone—ankylosing spondylitis	0.0015	0.0104	CcSEcCtD
Bosutinib—Acne—Betamethasone—ankylosing spondylitis	0.0015	0.0104	CcSEcCtD
Bosutinib—Fluid retention—Prednisolone—ankylosing spondylitis	0.00144	0.00997	CcSEcCtD
Bosutinib—EPHB2—Diflorasone—Methylprednisolone—ankylosing spondylitis	0.00142	0.0973	CbGdCrCtD
Bosutinib—EPHB2—Diflorasone—Betamethasone—ankylosing spondylitis	0.0014	0.0957	CbGdCrCtD
Bosutinib—EPHB2—Diflorasone—Dexamethasone—ankylosing spondylitis	0.0014	0.0957	CbGdCrCtD
Bosutinib—ABCB1—Betamethasone—ankylosing spondylitis	0.00137	0.108	CbGbCtD
Bosutinib—EPHB2—Diflorasone—Triamcinolone—ankylosing spondylitis	0.00136	0.0935	CbGdCrCtD
Bosutinib—ABCB1—Prednisolone—ankylosing spondylitis	0.00135	0.107	CbGbCtD
Bosutinib—PDGFRB—tendon—ankylosing spondylitis	0.00134	0.00544	CbGeAlD
Bosutinib—Fluid retention—Triamcinolone—ankylosing spondylitis	0.00132	0.00917	CcSEcCtD
Bosutinib—Fluid retention—Methylprednisolone—ankylosing spondylitis	0.00132	0.00915	CcSEcCtD
Bosutinib—Acne—Prednisone—ankylosing spondylitis	0.00131	0.00907	CcSEcCtD
Bosutinib—EPHB2—Diflorasone—Prednisone—ankylosing spondylitis	0.00129	0.0888	CbGdCrCtD
Bosutinib—ABCB1—Prednisone—ankylosing spondylitis	0.00128	0.101	CbGbCtD
Bosutinib—EPHB2—Diflorasone—Prednisolone—ankylosing spondylitis	0.00126	0.0866	CbGdCrCtD
Bosutinib—CYP3A4—Methylprednisolone—ankylosing spondylitis	0.00126	0.0999	CbGbCtD
Bosutinib—Pleural effusion—Methotrexate—ankylosing spondylitis	0.0012	0.00833	CcSEcCtD
Bosutinib—Fluid retention—Betamethasone—ankylosing spondylitis	0.0012	0.00832	CcSEcCtD
Bosutinib—Fluid retention—Dexamethasone—ankylosing spondylitis	0.0012	0.00832	CcSEcCtD
Bosutinib—ABL1—tendon—ankylosing spondylitis	0.00119	0.00485	CbGeAlD
Bosutinib—Hepatotoxicity—Methotrexate—ankylosing spondylitis	0.00119	0.00826	CcSEcCtD
Bosutinib—Fluid retention—Prednisone—ankylosing spondylitis	0.00105	0.00725	CcSEcCtD
Bosutinib—CYP3A4—Triamcinolone—ankylosing spondylitis	0.000956	0.0757	CbGbCtD
Bosutinib—Respiratory failure—Methotrexate—ankylosing spondylitis	0.000938	0.00649	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Methylprednisolone—ankylosing spondylitis	0.000891	0.00617	CcSEcCtD
Bosutinib—Influenza—Triamcinolone—ankylosing spondylitis	0.000875	0.00606	CcSEcCtD
Bosutinib—Bronchitis—Triamcinolone—ankylosing spondylitis	0.000842	0.00583	CcSEcCtD
Bosutinib—CYP3A4—Betamethasone—ankylosing spondylitis	0.00082	0.0649	CbGbCtD
Bosutinib—Upper respiratory tract infection—Triamcinolone—ankylosing spondylitis	0.000814	0.00563	CcSEcCtD
Bosutinib—CYP3A4—Prednisolone—ankylosing spondylitis	0.000809	0.0641	CbGbCtD
Bosutinib—Gastrointestinal haemorrhage—Prednisone—ankylosing spondylitis	0.0008	0.00554	CcSEcCtD
Bosutinib—ABCB1—Dexamethasone—ankylosing spondylitis	0.000796	0.063	CbGbCtD
Bosutinib—Infestation NOS—Methylprednisolone—ankylosing spondylitis	0.000779	0.00539	CcSEcCtD
Bosutinib—Infestation—Methylprednisolone—ankylosing spondylitis	0.000779	0.00539	CcSEcCtD
Bosutinib—Face oedema—Prednisone—ankylosing spondylitis	0.000773	0.00535	CcSEcCtD
Bosutinib—CYP3A4—Prednisone—ankylosing spondylitis	0.000764	0.0605	CbGbCtD
Bosutinib—PKMYT1—Danazol—Prednisone—ankylosing spondylitis	0.000734	0.0504	CbGdCrCtD
Bosutinib—Renal failure acute—Methotrexate—ankylosing spondylitis	0.000724	0.00501	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Prednisone—ankylosing spondylitis	0.000706	0.00489	CcSEcCtD
Bosutinib—CSNK1E—Danazol—Prednisone—ankylosing spondylitis	0.000701	0.048	CbGdCrCtD
Bosutinib—Connective tissue disorder—Methylprednisolone—ankylosing spondylitis	0.000687	0.00476	CcSEcCtD
Bosutinib—Cardiac disorder—Methylprednisolone—ankylosing spondylitis	0.000649	0.00449	CcSEcCtD
Bosutinib—Neutropenia—Prednisone—ankylosing spondylitis	0.000647	0.00448	CcSEcCtD
Bosutinib—ABCB1—Methotrexate—ankylosing spondylitis	0.00064	0.0507	CbGbCtD
Bosutinib—Immune system disorder—Methylprednisolone—ankylosing spondylitis	0.000631	0.00437	CcSEcCtD
Bosutinib—Mediastinal disorder—Methylprednisolone—ankylosing spondylitis	0.00063	0.00436	CcSEcCtD
Bosutinib—Ill-defined disorder—Prednisolone—ankylosing spondylitis	0.000615	0.00426	CcSEcCtD
Bosutinib—Malnutrition—Methylprednisolone—ankylosing spondylitis	0.000609	0.00421	CcSEcCtD
Bosutinib—Malaise—Prednisolone—ankylosing spondylitis	0.000598	0.00414	CcSEcCtD
Bosutinib—Dysgeusia—Triamcinolone—ankylosing spondylitis	0.000597	0.00413	CcSEcCtD
Bosutinib—Back pain—Triamcinolone—ankylosing spondylitis	0.00059	0.00408	CcSEcCtD
Bosutinib—Ill-defined disorder—Triamcinolone—ankylosing spondylitis	0.000566	0.00392	CcSEcCtD
Bosutinib—Ill-defined disorder—Methylprednisolone—ankylosing spondylitis	0.000565	0.00391	CcSEcCtD
Bosutinib—Discomfort—Prednisolone—ankylosing spondylitis	0.000558	0.00386	CcSEcCtD
Bosutinib—Abdominal discomfort—Methotrexate—ankylosing spondylitis	0.000554	0.00384	CcSEcCtD
Bosutinib—Malaise—Triamcinolone—ankylosing spondylitis	0.00055	0.00381	CcSEcCtD
Bosutinib—Pancytopenia—Methotrexate—ankylosing spondylitis	0.000549	0.0038	CcSEcCtD
Bosutinib—Malaise—Methylprednisolone—ankylosing spondylitis	0.000549	0.0038	CcSEcCtD
Bosutinib—Connective tissue disorder—Prednisone—ankylosing spondylitis	0.000544	0.00377	CcSEcCtD
Bosutinib—Oedema—Prednisolone—ankylosing spondylitis	0.000541	0.00375	CcSEcCtD
Bosutinib—Anaphylactic shock—Prednisolone—ankylosing spondylitis	0.000541	0.00375	CcSEcCtD
Bosutinib—Neutropenia—Methotrexate—ankylosing spondylitis	0.000541	0.00374	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Methotrexate—ankylosing spondylitis	0.000537	0.00372	CcSEcCtD
Bosutinib—Cough—Triamcinolone—ankylosing spondylitis	0.000532	0.00368	CcSEcCtD
Bosutinib—Myalgia—Triamcinolone—ankylosing spondylitis	0.000519	0.00359	CcSEcCtD
Bosutinib—Pneumonia—Methotrexate—ankylosing spondylitis	0.000518	0.00359	CcSEcCtD
Bosutinib—Myalgia—Methylprednisolone—ankylosing spondylitis	0.000518	0.00359	CcSEcCtD
Bosutinib—Arthralgia—Methylprednisolone—ankylosing spondylitis	0.000518	0.00359	CcSEcCtD
Bosutinib—Infestation—Methotrexate—ankylosing spondylitis	0.000515	0.00357	CcSEcCtD
Bosutinib—Infestation NOS—Methotrexate—ankylosing spondylitis	0.000515	0.00357	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.000515	0.00356	CcSEcCtD
Bosutinib—Ill-defined disorder—Betamethasone—ankylosing spondylitis	0.000513	0.00355	CcSEcCtD
Bosutinib—Ill-defined disorder—Dexamethasone—ankylosing spondylitis	0.000513	0.00355	CcSEcCtD
Bosutinib—Discomfort—Triamcinolone—ankylosing spondylitis	0.000513	0.00355	CcSEcCtD
Bosutinib—Discomfort—Methylprednisolone—ankylosing spondylitis	0.000512	0.00354	CcSEcCtD
Bosutinib—Renal failure—Methotrexate—ankylosing spondylitis	0.000507	0.00351	CcSEcCtD
Bosutinib—Immune system disorder—Prednisone—ankylosing spondylitis	0.0005	0.00346	CcSEcCtD
Bosutinib—Malaise—Betamethasone—ankylosing spondylitis	0.000499	0.00345	CcSEcCtD
Bosutinib—Malaise—Dexamethasone—ankylosing spondylitis	0.000499	0.00345	CcSEcCtD
Bosutinib—Anaphylactic shock—Triamcinolone—ankylosing spondylitis	0.000498	0.00345	CcSEcCtD
Bosutinib—Oedema—Triamcinolone—ankylosing spondylitis	0.000498	0.00345	CcSEcCtD
Bosutinib—Anaphylactic shock—Methylprednisolone—ankylosing spondylitis	0.000497	0.00344	CcSEcCtD
Bosutinib—Infection—Triamcinolone—ankylosing spondylitis	0.000495	0.00342	CcSEcCtD
Bosutinib—Infection—Methylprednisolone—ankylosing spondylitis	0.000493	0.00342	CcSEcCtD
Bosutinib—CSNK1E—Dexamethasone—Methylprednisolone—ankylosing spondylitis	0.00049	0.0336	CbGdCrCtD
Bosutinib—CSNK1E—Betamethasone—Methylprednisolone—ankylosing spondylitis	0.00049	0.0336	CbGdCrCtD
Bosutinib—Hepatobiliary disease—Methotrexate—ankylosing spondylitis	0.000487	0.00337	CcSEcCtD
Bosutinib—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.000487	0.00337	CcSEcCtD
Bosutinib—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.000482	0.00334	CcSEcCtD
Bosutinib—CSNK1E—Dexamethasone—Betamethasone—ankylosing spondylitis	0.000482	0.0331	CbGdCrCtD
Bosutinib—CSNK1E—Betamethasone—Dexamethasone—ankylosing spondylitis	0.000482	0.0331	CbGdCrCtD
Bosutinib—Malnutrition—Prednisone—ankylosing spondylitis	0.000482	0.00334	CcSEcCtD
Bosutinib—Agranulocytosis—Methotrexate—ankylosing spondylitis	0.000481	0.00333	CcSEcCtD
Bosutinib—CYP3A4—Dexamethasone—ankylosing spondylitis	0.000477	0.0378	CbGbCtD
Bosutinib—CSNK1E—Betamethasone—Triamcinolone—ankylosing spondylitis	0.000471	0.0323	CbGdCrCtD
Bosutinib—CSNK1E—Dexamethasone—Triamcinolone—ankylosing spondylitis	0.000471	0.0323	CbGdCrCtD
Bosutinib—Myalgia—Dexamethasone—ankylosing spondylitis	0.000471	0.00326	CcSEcCtD
Bosutinib—Myalgia—Betamethasone—ankylosing spondylitis	0.000471	0.00326	CcSEcCtD
Bosutinib—Discomfort—Betamethasone—ankylosing spondylitis	0.000465	0.00322	CcSEcCtD
Bosutinib—Discomfort—Dexamethasone—ankylosing spondylitis	0.000465	0.00322	CcSEcCtD
Bosutinib—Pain—Prednisolone—ankylosing spondylitis	0.000463	0.0032	CcSEcCtD
Bosutinib—Hepatitis—Methotrexate—ankylosing spondylitis	0.000463	0.0032	CcSEcCtD
Bosutinib—Urinary tract disorder—Methotrexate—ankylosing spondylitis	0.000457	0.00316	CcSEcCtD
Bosutinib—Urethral disorder—Methotrexate—ankylosing spondylitis	0.000454	0.00314	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	0.000453	0.00314	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	0.000452	0.00313	CcSEcCtD
Bosutinib—Anaphylactic shock—Betamethasone—ankylosing spondylitis	0.000452	0.00313	CcSEcCtD
Bosutinib—Anaphylactic shock—Dexamethasone—ankylosing spondylitis	0.000452	0.00313	CcSEcCtD
Bosutinib—Oedema—Dexamethasone—ankylosing spondylitis	0.000452	0.00313	CcSEcCtD
Bosutinib—Oedema—Betamethasone—ankylosing spondylitis	0.000452	0.00313	CcSEcCtD
Bosutinib—Infection—Dexamethasone—ankylosing spondylitis	0.000449	0.00311	CcSEcCtD
Bosutinib—Infection—Betamethasone—ankylosing spondylitis	0.000449	0.00311	CcSEcCtD
Bosutinib—CSNK1E—Dexamethasone—Prednisone—ankylosing spondylitis	0.000447	0.0307	CbGdCrCtD
Bosutinib—CSNK1E—Betamethasone—Prednisone—ankylosing spondylitis	0.000447	0.0307	CbGdCrCtD
Bosutinib—Ill-defined disorder—Prednisone—ankylosing spondylitis	0.000447	0.0031	CcSEcCtD
Bosutinib—Feeling abnormal—Prednisolone—ankylosing spondylitis	0.000446	0.00309	CcSEcCtD
Bosutinib—Anaemia—Prednisone—ankylosing spondylitis	0.000445	0.00308	CcSEcCtD
Bosutinib—Dyspnoea—Triamcinolone—ankylosing spondylitis	0.000444	0.00307	CcSEcCtD
Bosutinib—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.000443	0.00307	CcSEcCtD
Bosutinib—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.000443	0.00307	CcSEcCtD
Bosutinib—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	0.000442	0.00306	CcSEcCtD
Bosutinib—Thrombocytopenia—Betamethasone—ankylosing spondylitis	0.000442	0.00306	CcSEcCtD
Bosutinib—Erythema multiforme—Methotrexate—ankylosing spondylitis	0.000437	0.00303	CcSEcCtD
Bosutinib—CSNK1E—Dexamethasone—Prednisolone—ankylosing spondylitis	0.000437	0.0299	CbGdCrCtD
Bosutinib—CSNK1E—Betamethasone—Prednisolone—ankylosing spondylitis	0.000437	0.0299	CbGdCrCtD
Bosutinib—Malaise—Prednisone—ankylosing spondylitis	0.000435	0.00301	CcSEcCtD
Bosutinib—Tinnitus—Methotrexate—ankylosing spondylitis	0.000431	0.00299	CcSEcCtD
Bosutinib—Urticaria—Prednisolone—ankylosing spondylitis	0.00043	0.00298	CcSEcCtD
Bosutinib—Cardiac disorder—Methotrexate—ankylosing spondylitis	0.000429	0.00297	CcSEcCtD
Bosutinib—Fatigue—Triamcinolone—ankylosing spondylitis	0.000429	0.00297	CcSEcCtD
Bosutinib—Fatigue—Methylprednisolone—ankylosing spondylitis	0.000428	0.00296	CcSEcCtD
Bosutinib—Pain—Triamcinolone—ankylosing spondylitis	0.000426	0.00295	CcSEcCtD
Bosutinib—Immune system disorder—Methotrexate—ankylosing spondylitis	0.000418	0.00289	CcSEcCtD
Bosutinib—Mediastinal disorder—Methotrexate—ankylosing spondylitis	0.000417	0.00289	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	0.000411	0.00285	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	0.000411	0.00285	CcSEcCtD
Bosutinib—Myalgia—Prednisone—ankylosing spondylitis	0.00041	0.00284	CcSEcCtD
Bosutinib—Arthralgia—Prednisone—ankylosing spondylitis	0.00041	0.00284	CcSEcCtD
Bosutinib—Feeling abnormal—Triamcinolone—ankylosing spondylitis	0.00041	0.00284	CcSEcCtD
Bosutinib—Feeling abnormal—Methylprednisolone—ankylosing spondylitis	0.000409	0.00283	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.000407	0.00282	CcSEcCtD
Bosutinib—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	0.000406	0.00281	CcSEcCtD
Bosutinib—Discomfort—Prednisone—ankylosing spondylitis	0.000405	0.00281	CcSEcCtD
Bosutinib—Malnutrition—Methotrexate—ankylosing spondylitis	0.000403	0.00279	CcSEcCtD
Bosutinib—Urticaria—Triamcinolone—ankylosing spondylitis	0.000395	0.00274	CcSEcCtD
Bosutinib—Urticaria—Methylprednisolone—ankylosing spondylitis	0.000395	0.00273	CcSEcCtD
Bosutinib—Dysgeusia—Methotrexate—ankylosing spondylitis	0.000394	0.00273	CcSEcCtD
Bosutinib—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.000393	0.00272	CcSEcCtD
Bosutinib—Oedema—Prednisone—ankylosing spondylitis	0.000393	0.00272	CcSEcCtD
Bosutinib—Anaphylactic shock—Prednisone—ankylosing spondylitis	0.000393	0.00272	CcSEcCtD
Bosutinib—Abdominal pain—Methylprednisolone—ankylosing spondylitis	0.000393	0.00272	CcSEcCtD
Bosutinib—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.000393	0.00272	CcSEcCtD
Bosutinib—Decreased appetite—Betamethasone—ankylosing spondylitis	0.000393	0.00272	CcSEcCtD
Bosutinib—Infection—Prednisone—ankylosing spondylitis	0.000391	0.0027	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.00039	0.0027	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.00039	0.0027	CcSEcCtD
Bosutinib—Back pain—Methotrexate—ankylosing spondylitis	0.00039	0.0027	CcSEcCtD
Bosutinib—Fatigue—Betamethasone—ankylosing spondylitis	0.000389	0.0027	CcSEcCtD
Bosutinib—Fatigue—Dexamethasone—ankylosing spondylitis	0.000389	0.0027	CcSEcCtD
Bosutinib—Pain—Betamethasone—ankylosing spondylitis	0.000386	0.00267	CcSEcCtD
Bosutinib—Pain—Dexamethasone—ankylosing spondylitis	0.000386	0.00267	CcSEcCtD
Bosutinib—Nervous system disorder—Prednisone—ankylosing spondylitis	0.000386	0.00267	CcSEcCtD
Bosutinib—Skin disorder—Prednisone—ankylosing spondylitis	0.000382	0.00264	CcSEcCtD
Bosutinib—Ill-defined disorder—Methotrexate—ankylosing spondylitis	0.000374	0.00259	CcSEcCtD
Bosutinib—Anaemia—Methotrexate—ankylosing spondylitis	0.000372	0.00258	CcSEcCtD
Bosutinib—Feeling abnormal—Dexamethasone—ankylosing spondylitis	0.000372	0.00258	CcSEcCtD
Bosutinib—Feeling abnormal—Betamethasone—ankylosing spondylitis	0.000372	0.00258	CcSEcCtD
Bosutinib—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	0.000369	0.00256	CcSEcCtD
Bosutinib—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	0.000369	0.00256	CcSEcCtD
Bosutinib—Malaise—Methotrexate—ankylosing spondylitis	0.000363	0.00251	CcSEcCtD
Bosutinib—Leukopenia—Methotrexate—ankylosing spondylitis	0.000361	0.0025	CcSEcCtD
Bosutinib—Urticaria—Betamethasone—ankylosing spondylitis	0.000359	0.00248	CcSEcCtD
Bosutinib—Urticaria—Dexamethasone—ankylosing spondylitis	0.000359	0.00248	CcSEcCtD
Bosutinib—CHEK2—Danazol—Prednisone—ankylosing spondylitis	0.000359	0.0246	CbGdCrCtD
Bosutinib—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	0.000358	0.00248	CcSEcCtD
Bosutinib—Dizziness—Prednisolone—ankylosing spondylitis	0.000358	0.00248	CcSEcCtD
Bosutinib—Asthenia—Triamcinolone—ankylosing spondylitis	0.000357	0.00247	CcSEcCtD
Bosutinib—Body temperature increased—Dexamethasone—ankylosing spondylitis	0.000357	0.00247	CcSEcCtD
Bosutinib—Body temperature increased—Betamethasone—ankylosing spondylitis	0.000357	0.00247	CcSEcCtD
Bosutinib—Abdominal pain—Betamethasone—ankylosing spondylitis	0.000357	0.00247	CcSEcCtD
Bosutinib—Abdominal pain—Dexamethasone—ankylosing spondylitis	0.000357	0.00247	CcSEcCtD
Bosutinib—Asthenia—Methylprednisolone—ankylosing spondylitis	0.000356	0.00247	CcSEcCtD
Bosutinib—Pruritus—Triamcinolone—ankylosing spondylitis	0.000352	0.00244	CcSEcCtD
Bosutinib—Cough—Methotrexate—ankylosing spondylitis	0.000351	0.00243	CcSEcCtD
Bosutinib—Pruritus—Methylprednisolone—ankylosing spondylitis	0.000351	0.00243	CcSEcCtD
Bosutinib—Arthralgia—Methotrexate—ankylosing spondylitis	0.000343	0.00237	CcSEcCtD
Bosutinib—Chest pain—Methotrexate—ankylosing spondylitis	0.000343	0.00237	CcSEcCtD
Bosutinib—Myalgia—Methotrexate—ankylosing spondylitis	0.000343	0.00237	CcSEcCtD
Bosutinib—Decreased appetite—Prednisone—ankylosing spondylitis	0.000342	0.00237	CcSEcCtD
Bosutinib—Rash—Prednisolone—ankylosing spondylitis	0.000341	0.00236	CcSEcCtD
Bosutinib—Dermatitis—Prednisolone—ankylosing spondylitis	0.000341	0.00236	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.000341	0.00236	CcSEcCtD
Bosutinib—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.00034	0.00235	CcSEcCtD
Bosutinib—Fatigue—Prednisone—ankylosing spondylitis	0.000339	0.00235	CcSEcCtD
Bosutinib—Headache—Prednisolone—ankylosing spondylitis	0.000339	0.00235	CcSEcCtD
Bosutinib—Discomfort—Methotrexate—ankylosing spondylitis	0.000339	0.00235	CcSEcCtD
Bosutinib—Dizziness—Triamcinolone—ankylosing spondylitis	0.000329	0.00228	CcSEcCtD
Bosutinib—Anaphylactic shock—Methotrexate—ankylosing spondylitis	0.000329	0.00228	CcSEcCtD
Bosutinib—Dizziness—Methylprednisolone—ankylosing spondylitis	0.000328	0.00227	CcSEcCtD
Bosutinib—Infection—Methotrexate—ankylosing spondylitis	0.000327	0.00226	CcSEcCtD
Bosutinib—Feeling abnormal—Prednisone—ankylosing spondylitis	0.000324	0.00224	CcSEcCtD
Bosutinib—Asthenia—Dexamethasone—ankylosing spondylitis	0.000324	0.00224	CcSEcCtD
Bosutinib—Asthenia—Betamethasone—ankylosing spondylitis	0.000324	0.00224	CcSEcCtD
Bosutinib—Nervous system disorder—Methotrexate—ankylosing spondylitis	0.000322	0.00223	CcSEcCtD
Bosutinib—Thrombocytopenia—Methotrexate—ankylosing spondylitis	0.000322	0.00223	CcSEcCtD
Bosutinib—Gastrointestinal pain—Prednisone—ankylosing spondylitis	0.000322	0.00223	CcSEcCtD
Bosutinib—Nausea—Prednisolone—ankylosing spondylitis	0.000322	0.00223	CcSEcCtD
Bosutinib—Pruritus—Betamethasone—ankylosing spondylitis	0.00032	0.00221	CcSEcCtD
Bosutinib—Pruritus—Dexamethasone—ankylosing spondylitis	0.00032	0.00221	CcSEcCtD
Bosutinib—Skin disorder—Methotrexate—ankylosing spondylitis	0.000319	0.00221	CcSEcCtD
Bosutinib—Vomiting—Triamcinolone—ankylosing spondylitis	0.000316	0.00219	CcSEcCtD
Bosutinib—Vomiting—Methylprednisolone—ankylosing spondylitis	0.000316	0.00219	CcSEcCtD
Bosutinib—Rash—Triamcinolone—ankylosing spondylitis	0.000314	0.00217	CcSEcCtD
Bosutinib—Dermatitis—Triamcinolone—ankylosing spondylitis	0.000314	0.00217	CcSEcCtD
Bosutinib—Rash—Methylprednisolone—ankylosing spondylitis	0.000313	0.00217	CcSEcCtD
Bosutinib—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.000313	0.00217	CcSEcCtD
Bosutinib—Urticaria—Prednisone—ankylosing spondylitis	0.000312	0.00216	CcSEcCtD
Bosutinib—Headache—Triamcinolone—ankylosing spondylitis	0.000312	0.00216	CcSEcCtD
Bosutinib—Headache—Methylprednisolone—ankylosing spondylitis	0.000311	0.00215	CcSEcCtD
Bosutinib—Abdominal pain—Prednisone—ankylosing spondylitis	0.000311	0.00215	CcSEcCtD
Bosutinib—Body temperature increased—Prednisone—ankylosing spondylitis	0.000311	0.00215	CcSEcCtD
Bosutinib—Diarrhoea—Betamethasone—ankylosing spondylitis	0.000309	0.00214	CcSEcCtD
Bosutinib—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.000309	0.00214	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	0.000299	0.00207	CcSEcCtD
Bosutinib—Dizziness—Betamethasone—ankylosing spondylitis	0.000299	0.00207	CcSEcCtD
Bosutinib—Dizziness—Dexamethasone—ankylosing spondylitis	0.000299	0.00207	CcSEcCtD
Bosutinib—Nausea—Triamcinolone—ankylosing spondylitis	0.000296	0.00205	CcSEcCtD
Bosutinib—Nausea—Methylprednisolone—ankylosing spondylitis	0.000295	0.00204	CcSEcCtD
Bosutinib—Dyspnoea—Methotrexate—ankylosing spondylitis	0.000293	0.00203	CcSEcCtD
Bosutinib—Vomiting—Dexamethasone—ankylosing spondylitis	0.000287	0.00199	CcSEcCtD
Bosutinib—Vomiting—Betamethasone—ankylosing spondylitis	0.000287	0.00199	CcSEcCtD
Bosutinib—Decreased appetite—Methotrexate—ankylosing spondylitis	0.000286	0.00198	CcSEcCtD
Bosutinib—Rash—Dexamethasone—ankylosing spondylitis	0.000285	0.00197	CcSEcCtD
Bosutinib—Rash—Betamethasone—ankylosing spondylitis	0.000285	0.00197	CcSEcCtD
Bosutinib—Dermatitis—Betamethasone—ankylosing spondylitis	0.000285	0.00197	CcSEcCtD
Bosutinib—Dermatitis—Dexamethasone—ankylosing spondylitis	0.000285	0.00197	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.000284	0.00196	CcSEcCtD
Bosutinib—Fatigue—Methotrexate—ankylosing spondylitis	0.000283	0.00196	CcSEcCtD
Bosutinib—Headache—Betamethasone—ankylosing spondylitis	0.000283	0.00196	CcSEcCtD
Bosutinib—Headache—Dexamethasone—ankylosing spondylitis	0.000283	0.00196	CcSEcCtD
Bosutinib—Asthenia—Prednisone—ankylosing spondylitis	0.000282	0.00195	CcSEcCtD
Bosutinib—Pain—Methotrexate—ankylosing spondylitis	0.000281	0.00195	CcSEcCtD
Bosutinib—Pruritus—Prednisone—ankylosing spondylitis	0.000278	0.00193	CcSEcCtD
Bosutinib—Feeling abnormal—Methotrexate—ankylosing spondylitis	0.000271	0.00188	CcSEcCtD
Bosutinib—Diarrhoea—Prednisone—ankylosing spondylitis	0.000269	0.00186	CcSEcCtD
Bosutinib—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	0.000269	0.00186	CcSEcCtD
Bosutinib—Nausea—Dexamethasone—ankylosing spondylitis	0.000268	0.00186	CcSEcCtD
Bosutinib—Nausea—Betamethasone—ankylosing spondylitis	0.000268	0.00186	CcSEcCtD
Bosutinib—Urticaria—Methotrexate—ankylosing spondylitis	0.000261	0.00181	CcSEcCtD
Bosutinib—Dizziness—Prednisone—ankylosing spondylitis	0.00026	0.0018	CcSEcCtD
Bosutinib—Body temperature increased—Methotrexate—ankylosing spondylitis	0.00026	0.0018	CcSEcCtD
Bosutinib—Abdominal pain—Methotrexate—ankylosing spondylitis	0.00026	0.0018	CcSEcCtD
Bosutinib—Vomiting—Prednisone—ankylosing spondylitis	0.00025	0.00173	CcSEcCtD
Bosutinib—Rash—Prednisone—ankylosing spondylitis	0.000248	0.00172	CcSEcCtD
Bosutinib—Dermatitis—Prednisone—ankylosing spondylitis	0.000248	0.00172	CcSEcCtD
Bosutinib—Headache—Prednisone—ankylosing spondylitis	0.000246	0.00171	CcSEcCtD
Bosutinib—Asthenia—Methotrexate—ankylosing spondylitis	0.000236	0.00163	CcSEcCtD
Bosutinib—Nausea—Prednisone—ankylosing spondylitis	0.000234	0.00162	CcSEcCtD
Bosutinib—Pruritus—Methotrexate—ankylosing spondylitis	0.000233	0.00161	CcSEcCtD
Bosutinib—Diarrhoea—Methotrexate—ankylosing spondylitis	0.000225	0.00156	CcSEcCtD
Bosutinib—Dizziness—Methotrexate—ankylosing spondylitis	0.000217	0.0015	CcSEcCtD
Bosutinib—Vomiting—Methotrexate—ankylosing spondylitis	0.000209	0.00145	CcSEcCtD
Bosutinib—Rash—Methotrexate—ankylosing spondylitis	0.000207	0.00143	CcSEcCtD
Bosutinib—Dermatitis—Methotrexate—ankylosing spondylitis	0.000207	0.00143	CcSEcCtD
Bosutinib—Headache—Methotrexate—ankylosing spondylitis	0.000206	0.00143	CcSEcCtD
Bosutinib—Nausea—Methotrexate—ankylosing spondylitis	0.000195	0.00135	CcSEcCtD
Bosutinib—CSK—Signaling Pathways—MMP3—ankylosing spondylitis	7.82e-05	0.000134	CbGpPWpGaD
Bosutinib—LCK—Disease—B3GNT2—ankylosing spondylitis	7.82e-05	0.000134	CbGpPWpGaD
Bosutinib—YES1—Immune System—CD79A—ankylosing spondylitis	7.81e-05	0.000134	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—HLA-C—ankylosing spondylitis	7.8e-05	0.000134	CbGpPWpGaD
Bosutinib—LYN—Innate Immune System—HLA-B—ankylosing spondylitis	7.75e-05	0.000133	CbGpPWpGaD
Bosutinib—CSNK1E—Disease—HLA-A—ankylosing spondylitis	7.74e-05	0.000133	CbGpPWpGaD
Bosutinib—ABL1—Innate Immune System—HLA-B—ankylosing spondylitis	7.71e-05	0.000133	CbGpPWpGaD
Bosutinib—PTK2B—Immune System—HLA-B—ankylosing spondylitis	7.71e-05	0.000132	CbGpPWpGaD
Bosutinib—FYN—Adaptive Immune System—CD40LG—ankylosing spondylitis	7.7e-05	0.000132	CbGpPWpGaD
Bosutinib—EPHA2—Developmental Biology—TNF—ankylosing spondylitis	7.7e-05	0.000132	CbGpPWpGaD
Bosutinib—HCK—Immune System—HLA-A—ankylosing spondylitis	7.7e-05	0.000132	CbGpPWpGaD
Bosutinib—BTK—Immune System—TLR4—ankylosing spondylitis	7.67e-05	0.000132	CbGpPWpGaD
Bosutinib—IRAK4—Immune System—CRP—ankylosing spondylitis	7.65e-05	0.000131	CbGpPWpGaD
Bosutinib—LYN—Immune System—HLA-C—ankylosing spondylitis	7.63e-05	0.000131	CbGpPWpGaD
Bosutinib—FYN—Innate Immune System—HLA-B—ankylosing spondylitis	7.63e-05	0.000131	CbGpPWpGaD
Bosutinib—PDGFRB—Adaptive Immune System—HLA-B—ankylosing spondylitis	7.6e-05	0.000131	CbGpPWpGaD
Bosutinib—ABL1—Immune System—HLA-C—ankylosing spondylitis	7.6e-05	0.000131	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—PTGER4—ankylosing spondylitis	7.6e-05	0.000131	CbGpPWpGaD
Bosutinib—MAP2K1—Innate Immune System—HLA-B—ankylosing spondylitis	7.59e-05	0.00013	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—PTGER4—ankylosing spondylitis	7.54e-05	0.00013	CbGpPWpGaD
Bosutinib—BLK—Immune System—HLA-B—ankylosing spondylitis	7.53e-05	0.000129	CbGpPWpGaD
Bosutinib—FYN—Immune System—HLA-C—ankylosing spondylitis	7.52e-05	0.000129	CbGpPWpGaD
Bosutinib—FGR—Immune System—HLA-B—ankylosing spondylitis	7.5e-05	0.000129	CbGpPWpGaD
Bosutinib—ABL1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	7.47e-05	0.000128	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—HLA-C—ankylosing spondylitis	7.47e-05	0.000128	CbGpPWpGaD
Bosutinib—LYN—Adaptive Immune System—HLA-B—ankylosing spondylitis	7.44e-05	0.000128	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—CD79A—ankylosing spondylitis	7.41e-05	0.000127	CbGpPWpGaD
Bosutinib—MAP2K1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	7.35e-05	0.000126	CbGpPWpGaD
Bosutinib—HCK—Immune System—CRP—ankylosing spondylitis	7.34e-05	0.000126	CbGpPWpGaD
Bosutinib—IRAK4—Immune System—TLR4—ankylosing spondylitis	7.33e-05	0.000126	CbGpPWpGaD
Bosutinib—FYN—Adaptive Immune System—HLA-B—ankylosing spondylitis	7.33e-05	0.000126	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—IL1A—ankylosing spondylitis	7.29e-05	0.000125	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—PTGER4—ankylosing spondylitis	7.26e-05	0.000125	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—PTGER4—ankylosing spondylitis	7.26e-05	0.000125	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—CD40LG—ankylosing spondylitis	7.25e-05	0.000125	CbGpPWpGaD
Bosutinib—ERBB4—Immune System—HLA-A—ankylosing spondylitis	7.25e-05	0.000125	CbGpPWpGaD
Bosutinib—MAP2K2—Innate Immune System—CRP—ankylosing spondylitis	7.17e-05	0.000123	CbGpPWpGaD
Bosutinib—PTK2B—Immune System—HLA-A—ankylosing spondylitis	7.14e-05	0.000123	CbGpPWpGaD
Bosutinib—HCK—Disease—HLA-A—ankylosing spondylitis	7.1e-05	0.000122	CbGpPWpGaD
Bosutinib—EGFR—MAPK Signaling Pathway—TNF—ankylosing spondylitis	7.08e-05	0.000122	CbGpPWpGaD
Bosutinib—PDGFRB—Adaptive Immune System—HLA-A—ankylosing spondylitis	7.04e-05	0.000121	CbGpPWpGaD
Bosutinib—HCK—Immune System—TLR4—ankylosing spondylitis	7.04e-05	0.000121	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—PTGER4—ankylosing spondylitis	7e-05	0.00012	CbGpPWpGaD
Bosutinib—PDGFRB—Innate Immune System—CRP—ankylosing spondylitis	7e-05	0.00012	CbGpPWpGaD
Bosutinib—BLK—Immune System—HLA-A—ankylosing spondylitis	6.97e-05	0.00012	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—CD79A—ankylosing spondylitis	6.97e-05	0.00012	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—CD79A—ankylosing spondylitis	6.96e-05	0.00012	CbGpPWpGaD
Bosutinib—FGR—Immune System—HLA-A—ankylosing spondylitis	6.95e-05	0.000119	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—IL1RN—ankylosing spondylitis	6.94e-05	0.000119	CbGpPWpGaD
Bosutinib—SRC—Disease—B3GNT2—ankylosing spondylitis	6.92e-05	0.000119	CbGpPWpGaD
Bosutinib—ERBB4—Immune System—CRP—ankylosing spondylitis	6.91e-05	0.000119	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—HLA-B—ankylosing spondylitis	6.9e-05	0.000118	CbGpPWpGaD
Bosutinib—LYN—Adaptive Immune System—HLA-A—ankylosing spondylitis	6.9e-05	0.000118	CbGpPWpGaD
Bosutinib—MAP2K2—Innate Immune System—TLR4—ankylosing spondylitis	6.87e-05	0.000118	CbGpPWpGaD
Bosutinib—LYN—Innate Immune System—CRP—ankylosing spondylitis	6.85e-05	0.000118	CbGpPWpGaD
Bosutinib—ABL1—Innate Immune System—CRP—ankylosing spondylitis	6.82e-05	0.000117	CbGpPWpGaD
Bosutinib—PTK2B—Immune System—CRP—ankylosing spondylitis	6.81e-05	0.000117	CbGpPWpGaD
Bosutinib—FYN—Adaptive Immune System—HLA-A—ankylosing spondylitis	6.79e-05	0.000117	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—IL1RN—ankylosing spondylitis	6.77e-05	0.000116	CbGpPWpGaD
Bosutinib—FYN—Innate Immune System—CRP—ankylosing spondylitis	6.74e-05	0.000116	CbGpPWpGaD
Bosutinib—MAP2K1—Innate Immune System—CRP—ankylosing spondylitis	6.71e-05	0.000115	CbGpPWpGaD
Bosutinib—PDGFRB—Innate Immune System—TLR4—ankylosing spondylitis	6.71e-05	0.000115	CbGpPWpGaD
Bosutinib—ERBB4—Disease—HLA-A—ankylosing spondylitis	6.69e-05	0.000115	CbGpPWpGaD
Bosutinib—EGFR—Adaptive Immune System—CD40LG—ankylosing spondylitis	6.65e-05	0.000114	CbGpPWpGaD
Bosutinib—BLK—Immune System—CRP—ankylosing spondylitis	6.65e-05	0.000114	CbGpPWpGaD
Bosutinib—LYN—Immune System—IL1RN—ankylosing spondylitis	6.63e-05	0.000114	CbGpPWpGaD
Bosutinib—ERBB4—Immune System—TLR4—ankylosing spondylitis	6.63e-05	0.000114	CbGpPWpGaD
Bosutinib—FGR—Immune System—CRP—ankylosing spondylitis	6.63e-05	0.000114	CbGpPWpGaD
Bosutinib—ABL1—Immune System—IL1RN—ankylosing spondylitis	6.6e-05	0.000113	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—PTGER4—ankylosing spondylitis	6.6e-05	0.000113	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—HLA-B—ankylosing spondylitis	6.59e-05	0.000113	CbGpPWpGaD
Bosutinib—LYN—Innate Immune System—TLR4—ankylosing spondylitis	6.57e-05	0.000113	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—MMP3—ankylosing spondylitis	6.54e-05	0.000112	CbGpPWpGaD
Bosutinib—ABL1—Innate Immune System—TLR4—ankylosing spondylitis	6.54e-05	0.000112	CbGpPWpGaD
Bosutinib—PTK2B—Immune System—TLR4—ankylosing spondylitis	6.53e-05	0.000112	CbGpPWpGaD
Bosutinib—ABCB1—Allograft Rejection—TNF—ankylosing spondylitis	6.53e-05	0.000112	CbGpPWpGaD
Bosutinib—FYN—Immune System—IL1RN—ankylosing spondylitis	6.53e-05	0.000112	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IL1RN—ankylosing spondylitis	6.49e-05	0.000112	CbGpPWpGaD
Bosutinib—EGFR—Immune System—HLA-C—ankylosing spondylitis	6.49e-05	0.000112	CbGpPWpGaD
Bosutinib—PTK2—Immune System—IL1A—ankylosing spondylitis	6.49e-05	0.000112	CbGpPWpGaD
Bosutinib—FYN—Innate Immune System—TLR4—ankylosing spondylitis	6.47e-05	0.000111	CbGpPWpGaD
Bosutinib—PTK2—Immune System—CD40LG—ankylosing spondylitis	6.45e-05	0.000111	CbGpPWpGaD
Bosutinib—MAP2K1—Innate Immune System—TLR4—ankylosing spondylitis	6.43e-05	0.00011	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—CD40LG—ankylosing spondylitis	6.41e-05	0.00011	CbGpPWpGaD
Bosutinib—YES1—Immune System—IL1A—ankylosing spondylitis	6.4e-05	0.00011	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—HLA-A—ankylosing spondylitis	6.39e-05	0.00011	CbGpPWpGaD
Bosutinib—EGFR—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	6.39e-05	0.00011	CbGpPWpGaD
Bosutinib—BLK—Immune System—TLR4—ankylosing spondylitis	6.38e-05	0.00011	CbGpPWpGaD
Bosutinib—YES1—Immune System—CD40LG—ankylosing spondylitis	6.36e-05	0.000109	CbGpPWpGaD
Bosutinib—FGR—Immune System—TLR4—ankylosing spondylitis	6.36e-05	0.000109	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—HLA-B—ankylosing spondylitis	6.35e-05	0.000109	CbGpPWpGaD
Bosutinib—EGFR—Adaptive Immune System—HLA-B—ankylosing spondylitis	6.33e-05	0.000109	CbGpPWpGaD
Bosutinib—LCK—Immune System—HLA-C—ankylosing spondylitis	6.26e-05	0.000107	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—PTGER4—ankylosing spondylitis	6.23e-05	0.000107	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—PTGER4—ankylosing spondylitis	6.15e-05	0.000106	CbGpPWpGaD
Bosutinib—PTK2—Immune System—HLA-B—ankylosing spondylitis	6.14e-05	0.000105	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—HLA-B—ankylosing spondylitis	6.1e-05	0.000105	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—CRP—ankylosing spondylitis	6.1e-05	0.000105	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—CD79A—ankylosing spondylitis	6.09e-05	0.000105	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—IL1A—ankylosing spondylitis	6.07e-05	0.000104	CbGpPWpGaD
Bosutinib—YES1—Immune System—HLA-B—ankylosing spondylitis	6.05e-05	0.000104	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—CD40LG—ankylosing spondylitis	6.04e-05	0.000104	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—CD79A—ankylosing spondylitis	5.95e-05	0.000102	CbGpPWpGaD
Bosutinib—ERBB3—Disease—HLA-A—ankylosing spondylitis	5.9e-05	0.000101	CbGpPWpGaD
Bosutinib—EGFR—Adaptive Immune System—HLA-A—ankylosing spondylitis	5.87e-05	0.000101	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—TLR4—ankylosing spondylitis	5.84e-05	0.0001	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—PTGER4—ankylosing spondylitis	5.83e-05	0.0001	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—CRP—ankylosing spondylitis	5.83e-05	0.0001	CbGpPWpGaD
Bosutinib—LYN—Immune System—CD79A—ankylosing spondylitis	5.82e-05	0.0001	CbGpPWpGaD
Bosutinib—ABL1—Immune System—CD79A—ankylosing spondylitis	5.79e-05	9.96e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—MMP3—ankylosing spondylitis	5.78e-05	9.93e-05	CbGpPWpGaD
Bosutinib—ROCK1—Developmental Biology—TNF—ankylosing spondylitis	5.78e-05	9.92e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—HLA-B—ankylosing spondylitis	5.74e-05	9.86e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—CD79A—ankylosing spondylitis	5.73e-05	9.85e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—IL1A—ankylosing spondylitis	5.72e-05	9.82e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—CD79A—ankylosing spondylitis	5.7e-05	9.79e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—HLA-A—ankylosing spondylitis	5.69e-05	9.77e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—CD40LG—ankylosing spondylitis	5.68e-05	9.77e-05	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—CD40LG—ankylosing spondylitis	5.68e-05	9.75e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—MMP3—ankylosing spondylitis	5.66e-05	9.72e-05	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—HLA-A—ankylosing spondylitis	5.65e-05	9.71e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL1RN—ankylosing spondylitis	5.64e-05	9.69e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—HLA-B—ankylosing spondylitis	5.62e-05	9.66e-05	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—CRP—ankylosing spondylitis	5.62e-05	9.65e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—HLA-A—ankylosing spondylitis	5.61e-05	9.64e-05	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—TLR4—ankylosing spondylitis	5.59e-05	9.6e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—MMP3—ankylosing spondylitis	5.57e-05	9.58e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—HLA-C—ankylosing spondylitis	5.54e-05	9.52e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—PTGER4—ankylosing spondylitis	5.49e-05	9.43e-05	CbGpPWpGaD
Bosutinib—SRC—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	5.45e-05	9.36e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL1RN—ankylosing spondylitis	5.44e-05	9.34e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—CRP—ankylosing spondylitis	5.43e-05	9.32e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—MMP3—ankylosing spondylitis	5.41e-05	9.29e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—HLA-B—ankylosing spondylitis	5.41e-05	9.29e-05	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—HLA-B—ankylosing spondylitis	5.4e-05	9.28e-05	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—TLR4—ankylosing spondylitis	5.38e-05	9.25e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—MMP3—ankylosing spondylitis	5.37e-05	9.22e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—CRP—ankylosing spondylitis	5.35e-05	9.19e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—HLA-A—ankylosing spondylitis	5.32e-05	9.14e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—TLR4—ankylosing spondylitis	5.2e-05	8.94e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—MMP3—ankylosing spondylitis	5.17e-05	8.89e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—MMP3—ankylosing spondylitis	5.17e-05	8.89e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—TLR4—ankylosing spondylitis	5.13e-05	8.81e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—CRP—ankylosing spondylitis	5.08e-05	8.72e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—HLA-A—ankylosing spondylitis	5.01e-05	8.61e-05	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—HLA-A—ankylosing spondylitis	5e-05	8.6e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—IL1A—ankylosing spondylitis	5e-05	8.58e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—MMP3—ankylosing spondylitis	4.99e-05	8.57e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—CRP—ankylosing spondylitis	4.97e-05	8.54e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—CD40LG—ankylosing spondylitis	4.97e-05	8.53e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—CD79A—ankylosing spondylitis	4.95e-05	8.51e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—IL1A—ankylosing spondylitis	4.88e-05	8.38e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—TLR4—ankylosing spondylitis	4.87e-05	8.36e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—CD40LG—ankylosing spondylitis	4.85e-05	8.33e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL1RN—ankylosing spondylitis	4.81e-05	8.27e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—PTGER4—ankylosing spondylitis	4.8e-05	8.24e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—CRP—ankylosing spondylitis	4.78e-05	8.21e-05	CbGpPWpGaD
Bosutinib—PTK2—Developmental Biology—TNF—ankylosing spondylitis	4.78e-05	8.2e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—IL1A—ankylosing spondylitis	4.77e-05	8.2e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—CD79A—ankylosing spondylitis	4.77e-05	8.2e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—TLR4—ankylosing spondylitis	4.77e-05	8.19e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—IL1A—ankylosing spondylitis	4.75e-05	8.16e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—CD40LG—ankylosing spondylitis	4.75e-05	8.15e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—HLA-B—ankylosing spondylitis	4.72e-05	8.12e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—CD40LG—ankylosing spondylitis	4.72e-05	8.12e-05	CbGpPWpGaD
Bosutinib—YES1—Developmental Biology—TNF—ankylosing spondylitis	4.71e-05	8.09e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—IL1A—ankylosing spondylitis	4.7e-05	8.07e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—MMP3—ankylosing spondylitis	4.7e-05	8.07e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—PTGER4—ankylosing spondylitis	4.68e-05	8.04e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IL1A—ankylosing spondylitis	4.67e-05	8.03e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—CD40LG—ankylosing spondylitis	4.67e-05	8.03e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—CD40LG—ankylosing spondylitis	4.65e-05	7.98e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—HLA-B—ankylosing spondylitis	4.61e-05	7.92e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—PTGER4—ankylosing spondylitis	4.58e-05	7.87e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—TLR4—ankylosing spondylitis	4.58e-05	7.87e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—HLA-B—ankylosing spondylitis	4.51e-05	7.76e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—PTGER4—ankylosing spondylitis	4.51e-05	7.75e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—HLA-B—ankylosing spondylitis	4.49e-05	7.72e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—PTGER4—ankylosing spondylitis	4.49e-05	7.71e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—HLA-B—ankylosing spondylitis	4.44e-05	7.64e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—MMP3—ankylosing spondylitis	4.44e-05	7.62e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—HLA-B—ankylosing spondylitis	4.42e-05	7.59e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—HLA-A—ankylosing spondylitis	4.38e-05	7.52e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—MMP3—ankylosing spondylitis	4.38e-05	7.52e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—HLA-A—ankylosing spondylitis	4.27e-05	7.34e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—CD79A—ankylosing spondylitis	4.22e-05	7.26e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—HLA-A—ankylosing spondylitis	4.18e-05	7.19e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—CRP—ankylosing spondylitis	4.18e-05	7.17e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—HLA-A—ankylosing spondylitis	4.16e-05	7.15e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—MMP3—ankylosing spondylitis	4.15e-05	7.13e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—HLA-A—ankylosing spondylitis	4.12e-05	7.07e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—HLA-A—ankylosing spondylitis	4.1e-05	7.04e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—CRP—ankylosing spondylitis	4.08e-05	7e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL1A—ankylosing spondylitis	4.06e-05	6.97e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—HLA-A—ankylosing spondylitis	4.04e-05	6.94e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—CD40LG—ankylosing spondylitis	4.04e-05	6.93e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—TLR4—ankylosing spondylitis	4e-05	6.88e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—CRP—ankylosing spondylitis	3.99e-05	6.86e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—CRP—ankylosing spondylitis	3.97e-05	6.82e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—HLA-A—ankylosing spondylitis	3.94e-05	6.78e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—CRP—ankylosing spondylitis	3.93e-05	6.75e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL1A—ankylosing spondylitis	3.91e-05	6.72e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—MMP3—ankylosing spondylitis	3.91e-05	6.72e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—CRP—ankylosing spondylitis	3.91e-05	6.71e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—TLR4—ankylosing spondylitis	3.91e-05	6.71e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PTGER4—ankylosing spondylitis	3.9e-05	6.7e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—CD40LG—ankylosing spondylitis	3.89e-05	6.68e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—HLA-B—ankylosing spondylitis	3.84e-05	6.6e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—TLR4—ankylosing spondylitis	3.83e-05	6.57e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—TLR4—ankylosing spondylitis	3.81e-05	6.54e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—HLA-A—ankylosing spondylitis	3.8e-05	6.53e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—HLA-A—ankylosing spondylitis	3.78e-05	6.5e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—TLR4—ankylosing spondylitis	3.77e-05	6.47e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PTGER4—ankylosing spondylitis	3.76e-05	6.45e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—TLR4—ankylosing spondylitis	3.75e-05	6.44e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—HLA-B—ankylosing spondylitis	3.7e-05	6.36e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Developmental Biology—TNF—ankylosing spondylitis	3.68e-05	6.31e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—HLA-A—ankylosing spondylitis	3.56e-05	6.11e-05	CbGpPWpGaD
Bosutinib—LYN—Developmental Biology—TNF—ankylosing spondylitis	3.51e-05	6.03e-05	CbGpPWpGaD
Bosutinib—ABL1—Developmental Biology—TNF—ankylosing spondylitis	3.5e-05	6e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL1A—ankylosing spondylitis	3.46e-05	5.95e-05	CbGpPWpGaD
Bosutinib—FYN—Developmental Biology—TNF—ankylosing spondylitis	3.46e-05	5.94e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—CD40LG—ankylosing spondylitis	3.44e-05	5.92e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Developmental Biology—TNF—ankylosing spondylitis	3.44e-05	5.91e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—B3GNT2—ankylosing spondylitis	3.43e-05	5.89e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—HLA-A—ankylosing spondylitis	3.43e-05	5.89e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MMP3—ankylosing spondylitis	3.42e-05	5.87e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—CRP—ankylosing spondylitis	3.39e-05	5.83e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MMP3—ankylosing spondylitis	3.33e-05	5.73e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PTGER4—ankylosing spondylitis	3.33e-05	5.71e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—HLA-A—ankylosing spondylitis	3.28e-05	5.64e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—HLA-B—ankylosing spondylitis	3.28e-05	5.63e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—CRP—ankylosing spondylitis	3.27e-05	5.62e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MMP3—ankylosing spondylitis	3.26e-05	5.61e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—TLR4—ankylosing spondylitis	3.25e-05	5.59e-05	CbGpPWpGaD
Bosutinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	3.22e-05	5.54e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MMP3—ankylosing spondylitis	3.21e-05	5.52e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MMP3—ankylosing spondylitis	3.2e-05	5.49e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—HLA-A—ankylosing spondylitis	3.17e-05	5.44e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—TLR4—ankylosing spondylitis	3.14e-05	5.39e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—HLA-A—ankylosing spondylitis	3.03e-05	5.21e-05	CbGpPWpGaD
Bosutinib—EGFR—Developmental Biology—TNF—ankylosing spondylitis	2.99e-05	5.13e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—CRP—ankylosing spondylitis	2.9e-05	4.97e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—HLA-A—ankylosing spondylitis	2.8e-05	4.81e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—TLR4—ankylosing spondylitis	2.78e-05	4.77e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MMP3—ankylosing spondylitis	2.78e-05	4.77e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MMP3—ankylosing spondylitis	2.67e-05	4.6e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—TNF—ankylosing spondylitis	2.55e-05	4.38e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MMP3—ankylosing spondylitis	2.37e-05	4.07e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—B3GNT2—ankylosing spondylitis	2.11e-05	3.63e-05	CbGpPWpGaD
